Hypertension, diabetes, and obesity are considered major risk factors for cardiovascular diseases and premature mortality worldwide. Furthermore, they have severe consequences on quality of life among patients. With increasing challenges facing the healthcare systems, pharmacists are well positioned to take on a greater role in the management of chronic diseases. The present study aims to investigate the impact of pharmacist counselling on the clinical outcomes (weight, mortality, blood pressure, blood glucose) of hypertensive, diabetic, and obese patients.
This will be a multicentric randomized, controlled trial comparing enhanced pharmacist care (which included independent patient assessment, counseling, and follow-up) with usual care in the UAE over a year. Generally, this research project will be conducted on 3 phases; 1. patients who suffer from elevated blood pressure will be Randomised into two groups, of which one of them will receive a standard care and the second one will receive pharmaceutical care. Both will be followed up to 26 weeks (an estimated period to monitor blood pressure change). 2. patients with diabetes will be identified and Randomised using the same approach and followed up to 12 weeks (In order to monitor the HbA1c ). 3. Patients with obesity (BMI is 30 or higher) will be Randomised and followed up to 16 weeks (according to the literature, this is the period required to monitor the BMI change). SPSS V26 will be used for Data analysis. This research will enable the determination of the effectiveness of pharmacist counseling and follow-up in improving the clinical outcomes of chronic diseases (diabetes, hypertension, and obese) patients, which has never been assessed in the UAE. * The provided evidence may help in the implementation of a new novel practice in the world, in which the pharmacist's roles are expanded and evolved to include continual counseling on chronic disease patients and follow up. Thus, reducing the burden, and ensure sustainability of the healthcare services in the UAE. * Publications in peer-reviewed journals (At least 3 papers are expected), both international and local and conference presentations will be attempted to share the findings of our research. Therefore, the study aims to: 1. To assess the impact of pharmacist counseling on the mortality rate of diabetic, hypertensive and obese patients. 2. To study the impact of pharmacist counseling on the morbidity rate of diabetic, hypertensive and obese patients. 3. To measure the effectiveness of pharmacist counseling on improving the blood pressure of hypertensive patients. 4. To evaluate the benefits of pharmacist counseling on blood glucose level among diabetic patients. 5. To examine the impact of pharmacist recommendations and medication review on the weight and cholesterol level among obese patients. 6. To investigate potential adverse effects may be induced upon pharmacist counseling. 7. To explore any drug-related problems may be induced by pharmacist interventions. 8. To study the satisfaction of diabetic, hypertensive, and obese patients with pharmacist counselling.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Enrollment
720
Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
Fasting plasma glucose
The device used will be glucometer and the results will be expressed in (mmol/L)
Time frame: Up to 3 months
Glycosylated haemoglobin (HbA1c)
An A1c test result gets reported as a percentage. The number represents the portion of hemoglobin proteins that are glycated, or holding glucose. The higher the percentage, the higher your blood sugar levels have been over the last few months. Less than 5.7% means you don't have diabetes. 5.7% to 6.4% signals pre-diabetes. 6.5% or higher means a diabetes diagnosis. 7% or lower is the goal for someone trying to manage their diabetes.
Time frame: 12 weeks
Adherence to oral hypoglycaemic agents
The Medication Adherence Reasons Scale (MAR-Scale) is a 20-item comprehensive scale that was developed to measure medication adherence.
Time frame: Up to 3 months
Drug-related problems
We will use a drug-related problems classification system developed by Prof. Salah (AbuRuz, S.M., Bulatova, N.R. \& Yousef, A.M. Validation of a comprehensive classification tool for treatment-related problems . Pharm World Sci 28, 222-232 (2006). https://doi.org/10.1007/s11096-006-9048-0 ) which includes six main categories for treatment-related problems (Indication, Effectiveness, Safety, Knowledge, Adherence and Miscellaneous)
Time frame: Up to 3 months
Blood pressure values
Sphygmomanometer will be used to measure systolic and diastolic pressure values.
Time frame: Up to 3 months
Weight
It will be reported in Kg
Time frame: 6 months
Cholesterol LDL-cholesterol Triglycerides Cholesterol LDL-cholesterol Triglycerides
The cholesterol home test kit will be used and results will be expressed in milligrams (mg) of cholesterol per deciliter (dL) of blood.
Time frame: 6 months
Knowledge about diabetes
Diabetes Knowledge Questionnaire (DKQ) will be used
Time frame: Up to 3 months
knowledge about hypertension
The HKT is a simple questionnaire for assessing and monitoring HBP knowledge. It is sensitive to differences in blood pressure control status and should provide a valid, reliable, and standardized measure of HBP knowledge with wide relevance.
Time frame: Up to 3 months
Medication adherance
he Medication Adherence Reasons Scale (MAR-Scale) is a 20-item comprehensive scale that was developed to measure medication adherence.
Time frame: Up to 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.